One thing that was new in the R&R presentation was the Net Present Value chart (towards the end of the slides) that Don said pharma was comfortable with. If you look at those valuations and if they do represent realistic valuations for the very near future (we are close to the top of the chart in terms of progress) and then assume RVX + Zenith is worth more than RVX alone (well duh!), then I can't see how investment bankers wouldn't be salivating all over a package like this because of the huge difference between current values and the NPV generated by the company. Another thing to consider regarding a combination would be that the dilutive effect that would occur would likely be relatively less for the combined entity vs if they were packaged for investment bankers individually. Who knows but nice to dream :)